TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00520013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study: NCT04542460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: A loop recorder is implanted i all patients in both study groups to investigate:~* Prevalence and severity of cardiac arrhythmias.~* Effect on detected arrhythmia, in particular ventricular tachyarrhythmia, of optimal medical therapy vs. coronary revascularization by PCI.~* Prevalence and severity of cardiac arrhythmias in CTO-patients with failed PCI.~* Indication for prophylactic ICD implantation in CTO-patients treated conservatively or by PCI and after failed PCI.~* Relation of arrhythmias to angina pectoris symptoms (CCS class), Quality of life questionnaire results and presence of myocardial reversible perfusion defects by CMRI.
Study: NCT02788201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 approved agents
Description: One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocin, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COXEN
Description: The CO eXpression ExtrapolatioN (COXEN) algorithm will be used to determine the next best therapy from among 75 Food and Drug Administration (FDA) approved agents (single agent or combination) in patients that have progressed on at least one chemotherapy regimen.
Study: NCT01053559

Intervention type: DRUG
Group type: OTHER
Intervention: certolizumab pegol
Description: 400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
Study: NCT01852825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-8237
Description: A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NAC
Description: 0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NAC
Description: 0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NAC
Description: 0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
Study: NCT02181478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
Study: NCT01059786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilators
Description: Additional treatment with bronchodilators may be indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilators
Description: Additional treatment with bronchodilators may be indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilators
Description: Additional treatment with bronchodilators may be indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilators
Description: Additional treatment with bronchodilators may be indicated.
Study: NCT02181478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given by IV during prep at 40mg/m2 for 5 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell transplantation
Description: The total dosage of hMSC will be 2x10\^6cells/kg (+/-20%).
Study: NCT03132103

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Vitamin D3

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Solar simulated radiation (SSR)

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SSR
Study: NCT01497509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000
Study: NCT01059786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilators
Description: Additional treatment with bronchodilators may be indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) Saline
Description: Additional treatment with intravenous (IV) saline may be indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) Saline
Description: Additional treatment with intravenous (IV) saline may be indicated.
Study: NCT03274427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basic drugs therapy of HCC by TACE
Description: Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basic drugs therapy of HCC by TACE
Description: Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
Study: NCT01059786

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) Saline
Description: Additional treatment with intravenous (IV) saline may be indicated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) Saline
Description: Additional treatment with intravenous (IV) saline may be indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) Saline
Description: Additional treatment with intravenous (IV) saline may be indicated.
Study: NCT03010254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF® IQ Extended Depth of Focus IOL
Description: Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL; intended for long-term use over the lifetime of the pseudophakic subject
Study: NCT03274427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basic drugs therapy of HCC by TACE
Description: Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
Study: NCT03010254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACRYSOF® IQ Monofocal IOL
Description: Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: IOL bilateral implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: IOL bilateral implantation
Study: NCT03274427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine hydrochloride
Description: Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
Study: NCT03614416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOXY device
Description: Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gold standard oximeter
Description: Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SaO2 sampling
Description: Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
Study: NCT01081301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living with Hope Program
Description: The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals.
Study: NCT04413903

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
Description: The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
Description: The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
Study: NCT03184987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 mcg
Description: Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 200/62.5/25 mcg
Description: Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
Study: NCT02288962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabergoline
Study: NCT03008902

Intervention type: PROCEDURE
Intervention: Near-infrared passive motion capture recording
Description: Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.

Intervention type: PROCEDURE
Intervention: Near-infrared passive motion capture recording
Description: Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
Study: NCT02905617

Intervention type: DEVICE
Intervention: Sientra 207 Silicone Gel Breast Implant
Description: The Sientra 207 Silicone Gel Breast Implant is a textured, round device with high-strength cohesive plus (HSC+) silicone gel fill.

Intervention type: DEVICE
Intervention: Sientra 207 Silicone Gel Breast Implant
Description: The Sientra 207 Silicone Gel Breast Implant is a textured, round device with high-strength cohesive plus (HSC+) silicone gel fill.
Study: NCT03523273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administration will match the study drug.
Study: NCT02157441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower uterine compression sutures
Description: intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
Study: NCT00273754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children in group two will receive an amount of normal saline equal to Caffeine
Study: NCT03081676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 1Mg Tablet
Description: Glimepiride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 1Mg Tablet
Description: Glimepiride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 1Mg Tablet
Description: Glimepiride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-like Peptide-1
Description: GLP-1 infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-like Peptide-1
Description: GLP-1 infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-Dependent Insulinotropic Polypeptide
Description: GIP-infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-Dependent Insulinotropic Polypeptide
Description: GIP-infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusion
Description: Placebo (saline)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Placebo (saline)
Study: NCT02963987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food and Beverage Portion Size
Description: Variations of Food and Beverage Portion Size (100% Baseline portions and increased 50% for 150% portions)
Study: NCT02180633

Intervention type: OTHER
Intervention: Optical Coherence Tomography Scan
Description: As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).

Intervention type: OTHER
Intervention: Optical Coherence Tomography Scan
Description: As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).
Study: NCT01765426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV suspension for intradermal administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV suspension for intradermal administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV suspension for intradermal administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV suspension for intradermal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS)
Study: NCT00888251

Intervention type: OTHER
Intervention: Comprehensive weight management program
Description: Full meal replacement, behaviorial modification, medical monitoring, exercise.